Requests that the FDA determine and permit ANDA applicants for Ubrogepant tablets, (50 mg and 100 mg) to submit section viii statements for Orange Book-listed U.S. Patents and associated dosage strengths and use codes listed.
🏛 Food and Drug Administration (FDA)FDA-2026-P-5992
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.